Therapy News and Research

RSS

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

Scientists and researchers from the Northern Illinois Proton Treatment and Research Center (NIPTRC) and Northern Illinois University along with their partners are developing a new imaging process using a proton beam that they believe will be a major medical breakthrough in the delivery of proton beam therapy for cancer patients.

25 Feb 2010

ESMO conference on sarcoma and gastrointestinal stromal tumour

More should be done across Europe to ensure that people with rare forms of cancer are not denied access to the best possible treatment, say the organizers of a major European cancer conference to be held in Milan on 9 and 10 March 2010.

25 Feb 2010

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

HIV/AIDS remains one of the world's most significant public health challenges, particularly in developing countries. The Human Immunodeficiency Virus (HIV-1), the variant responsible for the pandemic, has the ability to infect different cell types such as T cells, macrophages and dendritic cells (DC). These latter cells are crucial in the defense against infectious agents and play a major role in viral pathogenesis.

25 Feb 2010

ESMO Conference to address issues relating to sarcoma and GIST

25 Feb 2010

Platelet function tests may predict heart attack, says study

An analysis of six tests that are used to measure platelet function and help gauge the effectiveness of antiplatelet drugs for patients undergoing a cardiac procedure such as a coronary stent implantation found that only three of the tests were associated with a modest ability to predict outcomes such as heart attack or death, according to a study in the February 24 issue of JAMA.

25 Feb 2010

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

US HIFU, a world leader in minimally invasive high intensity focused ultrasound (HIFU) technologies and manufacturer of the Sonablate® 500 medical device, has announced its intention to fund a landmark multi-center trial to study focal therapy for localized prostate cancer. Mark Emberton, M.D., (FRCS-Urology), consultant urological surgeon and divisional clinical director of cancer services at University College London Hospital (UCLH), along with Hashim Uddin Ahmed, MRC clinical research fellow, will lead the trial.

25 Feb 2010

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

An international research team led by Columbia University Medical Center successfully used mouse embryonic stem cells to replace diseased retinal cells and restore sight in a mouse model of retinitis pigmentosa. This strategy could potentially become a new treatment for retinitis pigmentosa, a leading cause of blindness that affects approximately one in 3,000 to 4,000 people, or 1.5 million people worldwide.

25 Feb 2010

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

MicroTransponder, Inc., a privately-held medical device company, has just announced a $7 Million Series B round of funding. MicroTransponder is developing a wireless neurostimulation platform for the treatment of chronic pain and other neurological indications.

25 Feb 2010

Identification of gaps in accessing stroke centers cuts down the deadly toll of stroke

When stroke strikes, choking off blood supply to the brain, every minute counts: Nearly 2 million neurons die each minute a stroke is left untreated, making it a race to recognize symptoms so that lifesaving "clot-busting" drugs can be administered.

25 Feb 2010

Rapamycin may hold promise for Alzheimer's disease

Rapamycin, a drug that keeps the immune system from attacking transplanted organs, may have another exciting use: fighting Alzheimer's disease.

25 Feb 2010

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Today, GlaxoSmithKline responded to the recently released Senate Committee on Finance's January 2010 "Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia" (the "Staff Report").

25 Feb 2010

Scientists one step closer to innovative drug delivery

A team of scientists led by Dr Simon Richardson at the University of Greenwich has got a step closer to one of the holy grails of drug delivery.

25 Feb 2010

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Women given the human immunodeficiency virus (HIV) prevention drug nevirapine to protect their fetus should not use an HIV-drug regimen that contains nevirapine for at least one year after childbirth, say researchers at the University of Alabama at Birmingham.

25 Feb 2010

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

Genentech, Inc., a wholly owned member of the Roche Group, today announced that a Phase III study showed the combination of Avastin® (bevacizumab) and chemotherapy followed by maintenance use of Avastin alone increased the time women with previously untreated advanced ovarian cancer lived without the disease worsening (progression-free survival or PFS), compared to chemotherapy alone. A preliminary assessment of safety noted adverse events previously observed in pivotal trials of Avastin.

25 Feb 2010

EpiCept provides business update and fourth-quarter financial highlights

EpiCept Corporation today announced operating and financial results for the fourth quarter and year ended December 31, 2009, and provided an update on Ceplene® and several of the Company’s key product candidates.

25 Feb 2010

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Harbor BioSciences, Inc. today announced that the company has received a notice of allowance from the United States Patent Office of patent claims covering the use of its lead product candidate Apoptone®. The patent claims cover the use of Apoptone to treat prostate cancer, breast cancer and benign prostatic hypertrophy. Apoptone (HE3235) is a novel synthetic steroid analog of a dihydrotestosterone metabolite and has been found to stimulate cell death (apoptosis) in animal models of prostate and breast cancers.

25 Feb 2010

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Post-menopausal women who reported consuming the most daily dietary fat had a 40 percent higher incidence of clot-caused strokes compared to women who ate the least amount, according to research presented at the American Stroke Association's International Stroke Conference 2010.

25 Feb 2010

Genetic Disorder Tracker introduced by Guidepoint Global

Guidepoint Global, LLC, a leading primary research firm, today announced the launch of their Genetic Disorder Tracker, a monthly longitudinal data release that captures commercial trends, on a worldwide basis, associated with the treatment of eight rare genetic disorders: Gaucher's disease, Fabry's disease, PKU, MPS I (Hurler Syndrome), MPS II (Hunter Syndrome), MPS VI (Maroteaux-Lamy Syndrome), Niemann-Pick disease and Pompe disease.

25 Feb 2010

Researchers to test Radio-embolisation technique in patients with bowel cancer

Cancer Research UK this week launches a new trial for patients with bowel cancer that has spread to the liver to see whether a new radiotherapy treatment technique is more effective than standard chemotherapy.

24 Feb 2010

Anthem Blue Cross will go forward with rate hikes, execs tell Calif. lawmakers

Anthem Blue Cross executives told California lawmakers Tuesday that they plan to go ahead with a rate hike of up to 39 percent for individual health insurance policies.

24 Feb 2010

Therapy News and Research

NIPTRC and partners announce development of new imaging process for proton beam therapy in cancer

ESMO conference on sarcoma and gastrointestinal stromal tumour

α-defensins1-3 may be potential prophylactic agents in treatment of HIV / AIDS

ESMO Conference to address issues relating to sarcoma and GIST

Platelet function tests may predict heart attack, says study

Focal therapy for localized prostate cancer: US HIFU announces intention to fund multi-center trial

Retinitis Pigmentosa: Embryonic stem cells for replacement of diseased retinal cells and restoration of sight

MicroTransponder awarded $2.6M NINDS SBIR FastTrack U44 grant, announces $7M Series B funding

Identification of gaps in accessing stroke centers cuts down the deadly toll of stroke

Rapamycin may hold promise for Alzheimer's disease

GlaxoSmithKline responds to Staff Report on GlaxoSmithKline and the Diabetes Drug Avandia

Scientists one step closer to innovative drug delivery

Nevirapine taken to protect fetus from HIV should be avoided for one year after childbirth, say researchers

Advanced ovarian cancer: Avastin-chemotherapy combination followed by Avastin alone improves PFS

EpiCept provides business update and fourth-quarter financial highlights

Harbor BioSciences to receive patent for Apoptone in treatment of prostate cancer, breast cancer and benign prostatic hypertrophy

Study examines associations of different fats and subtypes of ischemic stroke in post-menopausal women

Genetic Disorder Tracker introduced by Guidepoint Global

Researchers to test Radio-embolisation technique in patients with bowel cancer

Anthem Blue Cross will go forward with rate hikes, execs tell Calif. lawmakers

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News